or Try an Advanced Search...

    Technical Analysis for OCS - Oculis Holding AG

    Grade Last Price % Change Price Change
    C 14.91 -0.73% -0.11
    OCS closed down 0.73 percent on Wednesday, November 20, 2024, on 60 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Up Up Down
    Historical OCS trend table...
    Date Alert Name Type % Chg
    NR7 Range Contraction 0.00%
    Oversold Stochastic Weakness 0.00%
    MACD Bearish Centerline Cross Bearish -0.73%
    Oversold Stochastic Weakness -0.73%
    Crossed Above 50 DMA Bullish 1.98%
    Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 1.98%
    Inside Day Range Contraction 1.98%
    Oversold Stochastic Weakness 1.98%
    Fell Below 50 DMA Bearish 5.45%
    Outside Day Range Expansion 5.45%
    Older End-of-Day Signals for OCS ...

       Recent Intraday Alerts

    Alert Time
    Possible NR7 about 18 hours ago
    Gap Down Closed about 22 hours ago
    Gapped Down (Full) about 22 hours ago
    Fell Below Previous Day's Low about 22 hours ago
    Down 2 % about 22 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    OCS Chart by TradingView
    Basic chart:

    Profile

    • Earnings date: Unknown
    Oculis Holding AG, a biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. Its product candidates in development includes OCS-01, a topical retinal candidate for diabetic macular edema; OCS-02, a topical biologic candidate for dry eye disease; and OCS-05, a disease modifying candidate for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Lausanne, Switzerland.
    Classification
    Sector: Financial Services
    Industry: Shell Companies
    Keywords: Medicine Biopharmaceutical Disease Organ Systems Diabetes Ophthalmology Glaucoma Diabetic Retinopathy Macular Edema Diabetic Macular Edema Blindness Dry Eye Disease Retinopathy

    Is OCS a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 13 Oculis to Present at the Stifel 2024 Healthcare Conference
    Nov 8 Oculis Holding Third Quarter 2024 Earnings: Misses Expectations
    Nov 7 Oculis Holding GAAP EPS of -$0.48
    Nov 7 Oculis Reports Q3 2024 Financial Results and Provides Company Updates
    Nov 4 Oculis: Lack Of Coverage Only Real Risk For This Solid Company
    Oct 30 Oculis Holding AG's (NASDAQ:OCS) largest shareholders are individual investors with 56% ownership, institutions own 39%
    Oct 21 Oculis Accelerates Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema and Expands its DIAMOND Program Committees
    Oct 15 Oculis’ DIAMOND Phase 3 Program in Diabetic Macular Edema to be Presented at Innovate Retina and Eyecelerator 2024
    Oct 2 Oculis Announces Appointment of Daniel S. Char as Chief Legal Officer
    Sep 19 Oculis and EURETINA Announce the Winner of the Inaugural Ramin Tadayoni Award
    See more OCS news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 18.0
    52 Week Low 9.6
    Average Volume 55,737
    200-Day Moving Average 12.53
    50-Day Moving Average 14.47
    20-Day Moving Average 16.11
    10-Day Moving Average 15.22
    Average True Range 0.71
    RSI (14) 45.65
    ADX 34.46
    +DI 20.43
    -DI 26.93
    Chandelier Exit (Long, 3 ATRs) 15.88
    Chandelier Exit (Short, 3 ATRs) 16.12
    Upper Bollinger Bands 18.41
    Lower Bollinger Band 13.81
    Percent B (%b) 0.24
    BandWidth 28.55
    MACD Line -0.04
    MACD Signal Line 0.29
    MACD Histogram -0.3347
    Fundamentals Value
    Market Cap 543.25 Million
    Num Shares 36.4 Million
    EPS -2.69
    Price-to-Earnings (P/E) Ratio -5.54
    Price-to-Sales 510.76
    Price-to-Book 3.79
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 15.59
    Resistance 3 (R3) 15.56 15.31 15.47
    Resistance 2 (R2) 15.31 15.14 15.32 15.43
    Resistance 1 (R1) 15.11 15.03 14.99 15.14 15.40
    Pivot Point 14.86 14.86 14.80 14.87 14.86
    Support 1 (S1) 14.66 14.69 14.54 14.69 14.42
    Support 2 (S2) 14.41 14.58 14.42 14.39
    Support 3 (S3) 14.21 14.41 14.35
    Support 4 (S4) 14.24